These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 36572014)

  • 1. Efficacy and Incidence of Treatment-Related Adverse Events of Thrombopoietin Receptor Agonists in Adults with Immune Thrombocytopenia: A Systematic Review and Network Meta-Analysis of Randomized Controlled Study.
    Liu Y; Zhang HX; Su J; Geng QC; Lin X; Feng CX
    Acta Haematol; 2023; 146(3):173-184. PubMed ID: 36572014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
    Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
    Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
    Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W
    Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of thrombopoietin receptor agonists in children and adults with persistent and chronic immune thrombocytopenia: a meta-analysis.
    Li T; Liu Q; Pu T; Liu J; Zhang A
    Expert Opin Pharmacother; 2023 Apr; 24(6):763-774. PubMed ID: 37010022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.
    Puavilai T; Thadanipon K; Rattanasiri S; Ingsathit A; McEvoy M; Attia J; Thakkinstian A
    Br J Haematol; 2020 Feb; 188(3):450-459. PubMed ID: 31423574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
    Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
    Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
    Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura.
    Zeng Y; Duan X; Xu J; Ni X
    Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD008235. PubMed ID: 21735426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials.
    Catalá-López F; Corrales I; Martín-Serrano G; Tobías A; Calvo G
    Med Clin (Barc); 2012 Oct; 139(10):421-9. PubMed ID: 22266082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis.
    Wojciechowski P; Wilson K; Nazir J; Pustułka I; Tytuła A; Smela B; Pochopien M; Vredenburg M; McCrae KR; Jurczak W
    Adv Ther; 2021 Jun; 38(6):3113-3128. PubMed ID: 33934279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials.
    Catalá-López F; Corrales I; de la Fuente-Honrubia C; González-Bermejo D; Martín-Serrano G; Montero D; Saint-Gerons DM
    Med Clin (Barc); 2015 Dec; 145(12):511-9. PubMed ID: 26051432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis.
    Zhang J; Liang Y; Ai Y; Li X; Xie J; Li Y; Zheng W; He R
    PLoS One; 2018; 13(6):e0198504. PubMed ID: 29856837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
    Lassandro G; Palladino V; Vecchio GCD; Palmieri VV; Corallo PC; Faienza MF; Giordano P
    Endocr Metab Immune Disord Drug Targets; 2021; 21(3):397-406. PubMed ID: 32473624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
    González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
    Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis.
    Yang R; Lin L; Yao H; Ji O; Shen Q
    Hematology; 2019 Dec; 24(1):290-299. PubMed ID: 30661482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Efficacy and Safety of Thrombopoietin Receptor Agonists in Adults With Thrombocytopenia: A Systematic Review and Network Meta-analysis of Randomized Controlled Trial.
    Deng J; Hu H; Huang F; Huang C; Huang Q; Wang L; Wu A; Yang J; Qin D; Zou W; Wu J
    Front Pharmacol; 2021; 12():704093. PubMed ID: 34393785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
    Atkinson K
    Clin J Oncol Nurs; 2019 Apr; 23(2):212-216. PubMed ID: 30880797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.
    Pulanić D; Bátorová A; Bodó I; Červinek L; Ionita I; Lissitchkov T; Melikyan A; Podolak-Dawidziak M
    Ann Hematol; 2023 Apr; 102(4):715-727. PubMed ID: 36826482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of immune thrombocytopenia during pregnancy with thrombopoietin receptor agonists.
    Rottenstreich A; Bussel JB
    Br J Haematol; 2023 Dec; 203(5):872-885. PubMed ID: 37830251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis.
    Zhang J; Liang Y; Ai Y; Li X; Xie J; Li Y; Zheng W; He R
    Sci Rep; 2018 Jan; 8(1):576. PubMed ID: 29330464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.